drugset
drugset / Trial / NCT05057221

Safety, Tolerability and Efficacy of Uproleselan (GMI-1271) in Patients With COVID-19 Pneumonia

NCT05057221 ↗

Phase 1/2 Terminated 6 enrolled Lena Napolitano, MD GlycoMimetics Incorporated · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to find out whether the drug uproleselan can help patients with severe COVID-19 pneumonia. Investigators will study both the side effects of the drug and assess if the drug will help patients recover more quickly and slow down the progression of acute respiratory failure.

Timeline

Start
2021-11-12
Primary completion
2022-03-09
Completion
2022-03-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Uproleselan Small molecule 20 mg/kg Intravenous

Indications

pneumonia